TLDR: Evogene is transitioning from a computational biology company to a pure-play AI company, driven by an $18.7 million deal involving the sale of its plant-related assets. This strategic pivot will allow Evogene to fully concentrate on its ChemPass AI platform for discovering novel small molecules in life science applications.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a company previously known for its computational biology expertise, has announced a significant strategic shift, transforming into a pure-play AI company. This pivot is fueled by an $18.7 million deal, which involves the divestiture of its plant-related assets and activities, including its subsidiary Evogene Seeds Ltd., to an undisclosed third party. The transaction is anticipated to conclude in the fourth quarter of 2025.
The financial arrangement for this deal includes an upfront cash payment of $10 million upon closing, with an additional $8.7 million in deferred payments spread over three years, contingent upon the achievement of specific milestones. This substantial capital injection is expected to bolster Evogene’s financial position significantly, providing the necessary resources to accelerate the development and commercialization of its flagship ChemPass AI platform.
ChemPass is an advanced AI-driven platform specifically designed for the discovery and development of new small molecules. Its primary applications are within the life sciences, encompassing pharmaceuticals and agriculture. The platform utilizes sophisticated machine learning algorithms and computational chemistry to predict and design molecules with desired properties, thereby aiming to drastically speed up the drug discovery and development process.
Ofer Haviv, CEO of Evogene, commented on this transformative move, stating, “This is a pivotal moment for Evogene. For over two decades, we have been at the forefront of computational biology, applying our unique capabilities to various biological fields. The success of our ChemPass platform, particularly in identifying promising small molecules, has demonstrated the immense potential of our AI capabilities. This strategic pivot allows us to fully focus our resources and expertise on becoming a leader in AI-driven discovery for the life sciences.”
The company believes that concentrating solely on the ChemPass platform will unlock greater value for its shareholders by streamlining operations and focusing on a high-growth, high-margin business segment. Early collaborations have already shown promising results for the ChemPass platform, and Evogene plans to expand its partnerships with companies in the pharmaceutical and agricultural sectors.
While divesting its plant-related assets, Evogene will retain other computational biology platforms, such as MicroPass (focused on microbiome-based products) and EvoBreed (genomic selection for crop improvement). These platforms will either be integrated into the ChemPass framework where synergistic opportunities exist or be spun off into separate entities if strategic advantages arise. The company also intends to continue exploring avenues to leverage its AI capabilities across other industries.
Also Read:
- Dassault Systèmes Forges Ahead with AI-Driven Industrial Transformation, Bolstering Key Sectors
- Healthcare’s AI Evolution: Strategic Vision as the Cornerstone for Transformation
This strategic redirection underscores the increasing importance of artificial intelligence in scientific discovery and development. Evogene’s objective is to revolutionize the process of discovering new molecules, leading to faster, more efficient, and more cost-effective development of new drugs, crop protection agents, and other vital life science products. The company anticipates that this focused approach will result in significant advancements and enhanced shareholder value in the coming years.
